What is HC Wainwright’s Forecast for PVLA FY2027 Earnings?

Palvella Therapeutics, Inc. (NASDAQ:PVLA) – Research analysts at HC Wainwright raised their FY2027 earnings estimates for shares of Palvella Therapeutics in a research report issued on Tuesday, February 24th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of ($3.43) per share for the year, up from their previous forecast of ($3.65). HC Wainwright has a “Buy” rating and a $255.00 price objective on the stock. The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for Palvella Therapeutics’ FY2028 earnings at ($1.84) EPS, FY2029 earnings at $2.19 EPS and FY2030 earnings at $11.56 EPS.

Several other equities analysts have also recently weighed in on the company. Craig Hallum began coverage on Palvella Therapeutics in a research note on Thursday, December 4th. They set a “buy” rating and a $175.00 target price on the stock. UBS Group reiterated a “buy” rating and issued a $143.00 price objective on shares of Palvella Therapeutics in a research note on Monday, December 15th. Canaccord Genuity Group lifted their target price on shares of Palvella Therapeutics from $148.00 to $204.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. BTIG Research boosted their price target on shares of Palvella Therapeutics from $192.00 to $215.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Oppenheimer restated an “outperform” rating and issued a $200.00 target price on shares of Palvella Therapeutics in a research note on Monday, December 15th. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Palvella Therapeutics has a consensus rating of “Buy” and a consensus target price of $176.44.

Palvella Therapeutics Trading Up 15.3%

Shares of PVLA stock opened at $148.34 on Thursday. The company has a market capitalization of $1.76 billion, a price-to-earnings ratio of -56.40 and a beta of -0.16. Palvella Therapeutics has a 1-year low of $18.23 and a 1-year high of $151.18. The stock’s fifty day simple moving average is $93.82 and its 200-day simple moving average is $79.34.

Hedge Funds Weigh In On Palvella Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PVLA. Invesco Ltd. lifted its stake in shares of Palvella Therapeutics by 11.6% in the fourth quarter. Invesco Ltd. now owns 54,273 shares of the company’s stock worth $5,681,000 after buying an additional 5,663 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Palvella Therapeutics in the fourth quarter valued at about $429,000. Virtus Investment Advisers LLC bought a new position in shares of Palvella Therapeutics in the fourth quarter worth about $282,000. Superstring Capital Management LP bought a new position in shares of Palvella Therapeutics in the fourth quarter worth about $2,666,000. Finally, Suvretta Capital Management LLC lifted its position in shares of Palvella Therapeutics by 8.5% during the 4th quarter. Suvretta Capital Management LLC now owns 892,400 shares of the company’s stock worth $93,408,000 after purchasing an additional 70,000 shares during the last quarter. Institutional investors and hedge funds own 40.11% of the company’s stock.

Insider Activity at Palvella Therapeutics

In related news, COO Kathleen Goin sold 4,302 shares of the firm’s stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $97.63, for a total value of $420,004.26. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 20.50% of the company’s stock.

Trending Headlines about Palvella Therapeutics

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: Positive Phase‑3 / late‑stage clinical news has driven investor enthusiasm — coverage and headlines about a late‑stage win for Palvella’s lead asset are cited as a major momentum driver. Palvella Therapeutics shares surge on positive Phase 3 trial results
• Positive Sentiment: HC Wainwright materially raised multi‑year EPS forecasts and bumped its price target to $255 (from $200), and the firm retains a Buy — analyst upgrades and a hawkish target boost sentiment and institutional interest. Palvella Therapeutics price target raised to $255 from $200 at H.C. Wainwright
• Positive Sentiment: Other firms have increased targets (Mizuho $250, BTIG $215, Chardan $210), signaling broad analyst conviction and adding buying pressure from funds tracking upgrades. Chardan Capital Boosts Palvella Therapeutics Price Target to $210.00
• Neutral Sentiment: Palvella priced an upsized public offering of 1.6M shares at $125 to raise roughly $200M (plus a 30‑day option on 240k shares). The proceeds will fund QTORIN programs and R&D (cash runway positive), but the issuance dilutes current shareholders and adds near‑term supply. Palvella Therapeutics Announces Pricing of Upsized Public Offering
• Negative Sentiment: Short interest rose ~22% in February to about 1.67M shares (~17.8% of float) with ~5.5 days to cover; sizable short positions can pressure the stock if trial/clinical timelines slip, though they can also amplify rallies in the near term. Insider sales have also been reported, which some investors view negatively. (No single article link provided in the feed.)

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.